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Allele-specific genome editing and correction of
disease-associated phenotypes in rats using the
CRISPR–Cas platform
K. Yoshimi1, T. Kaneko1, B. Voigt1 & T. Mashimo1
The bacterial CRISPR/Cas system has proven to be an efficient gene-targeting tool in various
organisms. Here we employ CRISPR/Cas for accurate and efficient genome editing in rats.
The synthetic chimeric guide RNAs (gRNAs) discriminate a single-nucleotide polymorphism
(SNP) difference in rat embryonic fibroblasts, allowing allele-specific genome editing of the
dominant phenotype in (F344DA)F1 hybrid embryos. Interestingly, the targeted allele,
initially assessed by the allele-specific gRNA, is repaired by an interallelic gene conversion
between homologous chromosomes. Using single-stranded oligodeoxynucleotides, we
recover three recessive phenotypes: the albino phenotype by SNP exchange; the non-agouti
phenotype by integration of a 19-bp DNA fragment; and the hooded phenotype by eliminating
a 7,098-bp insertional DNA fragment, evolutionary-derived from an endogenous retrovirus.
Successful in vivo application of the CRISPR/Cas system confirms its importance as a genetic
engineering tool for creating animal models of human diseases and its potential use in gene
therapy.
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T
he laboratory rat, Rattus norvegicus, is a widely used
animal model for studying human diseases, such as
hypertension1, diabetes2, neurological disorders3 and for
testing the efficacy and toxicity of drugs. Because of its
larger body size compared with mice and their physiological
properties, which are being shared with humans, the rat is often
employed as an animal model in translational research4,5.
Recent progress in the development of genome engineering
tools in rats, such as zinc-finger nucleases (ZFNs)6–8 and
transcription activator-like effector nucleases (TALENs)9,10,
could provide genetically modified animals for gene annotation,
as well as for modelling human genetic disorders. These
engineered nucleases can recognize long stretches of DNA
sequences and introduce DNA double-strand breaks (DSBs),
which are generally restored via non-homologous end-joining, a
process that introduces small insertions or deletions (indels) at
the repair junction, thereby generating knockouts (KOs) at the
targeted sequences. Targeted knock-ins (KIs) can also be
engineered via homology-directed repair (HDR) by co-injection
into fertilized eggs of donor plasmids containing two flanked
homology arms together with any of the above mentioned
nucleases6,11,12. Although the nuclease-driven production of
targeted KOs or KIs is simple and fast, HDR-mediated KIs are
less efficiently to obtain.
Over the last decade, the emergent technology of next-
generation sequencing, which has powered genome-wide associa-
tion studies, has successfully identified numerous common single-
nucleotide polymorphisms (SNPs) associated with important
human diseases13–15. Many structural sequence variations, such
as small-scale indels, copy-number variations and large
chromosomal rearrangements have been identified16,17. To test
these particular structural variants in model animals, accurate
genome editing is required to produce equivalent mutations to
human variants rather than producing only simple KO models
where entire coding genes are rendered non-functional.
The bacterial CRISPR/Cas system has been shown to be an
efficient gene-targeting technology in mammalian cells18–20 and
many organisms21–25, including mice26,27 and rats12,28,29. The
system consists of clustered regularly interspaced short
palindromic repeats (CRISPRs) that produce RNA components
and the CRISPR-associated (Cas) nuclease protein30–32. The
CRISPR RNAs (crRNAs), which contain a short stretch of
homology to a specific target DNA, act as guides to direct Cas
nucleases to introduce DSBs at the targeted DNA sequences. A
synthetic chimeric guide RNA (gRNA), consisting of a fusion
between crRNA and trans-activating crRNA, has been shown to
direct Cas9 cleavage of target DNAs that are complementary to
the crRNA. In addition to the rapid creation of synthetic
gRNAs, a significant advantage of the CRISPR/Cas system is its
ability to target several genes simultaneously with multiple
gRNAs (multiplex gene editing). Another advantage of the
CRISPR/Cas system has been described from findings in
mice26,27,33. These results suggest that co-injected single-
stranded oligodeoxynucleotides (ssODNs) as donor templates
preferentially support the activation of HDR relative to the
non-homologous end-joining pathway.
In this study, we construct CRISPR/Cas architectures in
rats, and show allele-specific KOs of the dominant allele
(Supplementary Fig. 1). We also correct the three recessive
coat-colour-associated phenotypes that are responsible for the
appearance of all ‘albino-white’ laboratory rats using a KI
approach that uses ssODN donor templates. These results
demonstrate the flexible in vivo genome-editing capability
of the CRISPR/Cas system and its usability for the creation
of genetically engineered animal models of human diseases
in rats.
Results
Accurate and efficient genome editing in rats. To test the fea-
sibility of genome editing using the CRISPR/Cas system in rats,
we first designed gRNA-targeting of the rat coat colour gene,
tyrosinase (Tyr) (Fig. 1a). To decrease the possibility of off-target
(OT) effects, we used software tools that can predict unique and
suitable target sites throughout the rat genome (crispr.mit.edu)34.
Then, we transfected plasmids expressing the engineered gRNA
and codon-optimized Cas9 into the cultured rat fibroblast-like
cell line (Rat-1) derived from Wistar rats. Compared with the
negative control, which comprised only Cas9-transfected cells, the
cells transfected with Cas9 and gRNA showed targeted cleavage of
the PCR products determined by the Surveyor (Cel-I) nuclease
assay (Fig. 1b). Sequence analysis of the targeted Tyr locus also
showed a wide variety of indel mutations with a targeted cleavage
efficiency of 31.6% (Supplementary Fig. 2).
Next, we investigated the capability of CRISPR/Cas to direct
targeted cleavage in rat embryos, by microinjection of 50 ngml 1
gRNA and 100 ngml 1 Cas9 messenger RNA (mRNA) into male
pronuclei of fertilized Wistar rat eggs (Table 1). After 16 h, 41 of
the 90 Cas9/gRNA-injected embryos differentiated normally
into two cells (45.6%). Of 34 PCR-amplified two-cell embryos,
14 (41.2%) showed a variety of indel mutations mediated by
CRISPR/Cas at the targeted Tyr locus (Fig. 1c). Furthermore, 10
two-cell Cas9/gRNA-injected embryos were transferred into a
pseudopregnant foster mother, and three of these embryos were
carried to term. Sequence analyses of their tail DNA revealed that
all these pups carried indel mutations that were heterozygous or
mosaic at the Tyr locus (Supplementary Fig. 3). Crossing these
founders with Wistar rats demonstrated that all of the CRISPR/
Cas-mediated mutations were faithfully transmitted to the next
generation (Supplementary Table 1). In addition, neither
insertions nor deletions were observed at any of the seven most
likely calculated OT sites identified across the whole rat genome
with a similarity to the targeted site of 3- to 5-bp mismatches
from the 20-bp binding sequences and protospacer adjacent motif
sequences (Supplementary Table 2).
In mice26,27, co-injection of gRNAs, Cas9 mRNA and ssODNs
has been reported to allow for precise HDR-mediated genome
editing. To test this, the pronuclei of Wistar rat eggs were
microinjected with gRNA, Cas9 mRNA and 50 ng ml 1 ssODN
(Table 1). Of the 38 two-cell developed and PCR-amplified
embryos, 5 (13.2%) showed various indel mutations at the
targeted loci. Surprisingly, 14 (36.8%) showed a precise SNP
exchange mediated by ssODN-HDR, among which two were
biallelic with indel mutations (#2-1 and #5-2) and three carried
homozygous KI alleles (#2-3, #5-4 and #6-2) at the Tyr locus
(Fig. 1d).
Allele-specific genome editing for a dominant phenotype. The
high efficiency of the CRISPR/Cas system-mediated genome
editing in rats prompted us to modify observable phenotypic
traits, or to replace disease-causing mutations as therapeutic
models of human diseases. In humans, mutations in the TYR gene
with impaired TYR protein levels lead to oculocutaneous albinism
type 1 (OCA1), characterized by hypopigmentation of the skin
and hair and distinctive ocular changes35. Albino rats carry a
single SNP mutation 896G4A in exon 2 of the Tyr gene resulting
in an Arg299His missense mutation, which was also reported in
human oculocutaneous albinism type 1A with lack of
pigmentation36,37. To test disease-specific genome editing using
the CRISPR/Cas system, we designed two gRNAs: gRNA:Tyrc for
the mutant allele (Tyrc) of albino F344 rats, and gRNA:TyrC
targeting the wild-type allele (TyrC) of agouti DA rats (Fig. 2a).
We also used TALENs for targeting the albino Tyrc allele as a
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control9. When we transfected plasmids expressing the Cas9 and
the allele-specific gRNA into rat embryonic fibroblasts (REFs)
derived from the albino F344 rats, cleavage activity was detected
by the Surveyor assay with gRNA:Tyrc, but not with gRNA:TyrC
(Fig. 2b). In contrast, in REFs derived from DA rats, gRNA:TyrC
exhibited cleavage activity, while gRNA:Tyrc did not (Fig. 2c).
Our previously designed TALENs, which were designed to target
only the albino Tyrc allele9, could in fact not distinguish between
the Tyr albino/non-albino allele and showed similar cleavage
activity in both F344 REFs and DA REFs (Fig. 2b,c). Sequence
analysis of the PCR products also confirmed that each gRNA
showed significant allele specificity in each of the F344 and DA
REF cell types (Fig. 2d; Supplementary Figs 4 and 5), whereas the
TALENs did not (Fig. 2d; Supplementary Fig. 6).
To investigate whether the allele-specific genome editing used
herein was feasible in embryos, we injected each gRNA with Cas9
mRNA into the fertilized eggs of (F344DA)F1 hybrids
(Table 2). Transferring the injected embryos into pseudopregnant
Wistar females resulted in 21 pups born from gRNA:Tyrc-injected
embryos and 23 pups born from gRNA:TyrC-injected embryos.
All of the pups injected with gRNA:Tyrc showed Agouti coat
colour (Fig. 2e), while seven out of 23 pups (30.4%) injected with
gRNA:TyrC showed albino- or mosaic-coloured coats (Fig. 2f).
Sequence analysis revealed that gRNA:Tyrc only induced indel
Table 1 | CRISPR/Cas-mediated genome editing in rat embryos.
Injected RNA Embryos injected Two-cell embryos (%) PCR-amplified (%) Knockout (%) Knock-in (%)
Cas9þ gRNA 90 41 (45.6) 34 (82.9) 14 (41.2) –
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Figure 1 | NHEJ-mediated KO and HDR-mediated KI in Wistar rats using the CRISPR/Cas system. (a) Schematic representation of the rat tyrosinase
(Tyr) gene. The magnified view illustrates the gRNA binding sites (blue) and the PAM sequences (green). Wistar albino rats carry a G896A SNP
mutation (orange) in exon 2 of the Tyr gene. (b) Plasmids expressing gRNA and codon-optimized Cas9 were transfected into Wistar-derived Rat-1
fibroblasts. The Surveyor (Cel-I) nuclease assay on exon 2 of Tyr showed targeted cleavage of the digested PCR products (indicated by arrowheads).
M: DNA marker phiX174-HaeIII digest. Cas9: Cas9-transfected Rat-1. Cas9 gRNA: Cas9 and gRNA plasmid -transfected Rat-1. (c) Microinjection of gRNA
and Cas9 mRNA into fertilized Wistar rat eggs. Sequence analysis of PCR products amplified from the genomic DNA of two-cell embryos showed
a wide variety of indel mutations mediated by NHEJ at the targeted Tyr exon 2 (see also Table 1). (d) Co-injection of gRNA, Cas9 mRNA, and ssODN into
fertilized Wistar rat eggs. Sequence analysis showed indel mutations at the targeted Tyr exon 2 as well as the precise SNP exchange mediated by
HDR that resulted in KI alleles (see also Table 1).
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Figure 2 | Allele-specific genome editing in F1 rats by the CRISPR/Cas system. (a) Schematic representation of gRNA:Tyrc targeting of the mutant allele
(Tyrc) of albino F344 rats and gRNA:TyrC targeting of the wild-type allele (TyrC) of agouti DA rats. (b) Plasmids expressing Cas9 and allele-specific
gRNA transfected into F344-derived rat REFs. Cleavage activity by the Surveyor assay was detected with gRNA:Tyrc and with TALENs targeting Tyrc (as a
positive control), but not with gRNA:TyrC. M: DNA marker phiX174-HaeIII digest. (c) In DA-derived REFs, cleavage activity was detected with gRNA:TyrC and
with TALENs targeting of Tyrc, but not with gRNA:Tyrc. (d) Sequence analysis of the colonies picked from subcloned PCR products from the cultured
REFs (b,c). The allele-specific gRNA, and gRNA:Tyrc and gRNA:TyrC showed allele-specific cleavage activity in F344 and DA REFs, respectively, but the TALENs
did not act in an allele-specific manner. Data represent the mean±s.d., n¼ 3. *Po0.005 by Student’s t-test. (e) Picture of gRNA:Tyrc-injected (F344 
DA)F1 and (F344  DA)F1 rats showing the Agouti coat-colour. (f) Some of the gRNA:TyrC-injected F1 rats had albino coloured coats (white arrow) or mosaic
coloured coats (grey arrow). (g) Sequence analysis for each of the gRNA-injected F1 hybrid rats. gRNA:Tyrc modified only the F344-allele (Tyrc), while
gRNA:TyrC modified only the DA-allele (TyrC) in the F1 hybrid rats. Data represent the mean±s.d., n¼ 3. *Po0.001 by Student’s t-test.
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mutations in the F344 Tyrc allele (6 mutations/21 alleles), while
gRNA:TyrC only did so in the DA TyrC allele (7/23) in F1 hybrid
embryos (Fig. 2g; Supplementary Figs 7 and 8). These findings
indicate that the CRISPR/Cas system can discriminate single-base
pair differences and target allele-specific DNA variants in
embryos. Another interesting finding of this allele-specific
targeting is that two of the seven (28.6%) albino coat colour F1
rats injected with gRNA:TyrC carried homologous F344 Tyrcal-
leles (Supplementary Fig. 8), suggesting that an interallelic gene
conversion event occurred between the CRISPR/Cas-mediated
DA allele and the non-modified F344 allele, in which the original
non-albino DA allele was allele-specifically cut and the untouched
albino F344 allele served as a repair template.
Recovery of recessive disease-associated mutations. To test
whether the CRISPR/Cas platform can be used to recover reces-
sive disease-associated phenotypes, we targeted three different
types of mutations associated with representative coat-colour
phenotypes in rats: albino (c) a SNP missense mutation in the Tyr
gene30, non-agouti (a) a 19-bp deletion in exon 2 of the Agouti-
signalling protein (Asip) gene31, and hooded (h) an integrated
7,098-bp endogenous retroviral element (ERV) within the first
intron of the Kit gene32 (Fig. 3a). F344 rats carry all three of these
mutations (c, a, h), while DA rats carry wild-type alleles (C, A, H).
First, to recover the albino phenotype, we co-injected a mix of
gRNA:Tyrc, Cas9 mRNA and an 80-bp ssODN of the TyrC allele
into F344 rat embryos (Table 3). Of the 13 pups delivered, one
pup (7.7%) showed a recovery of the coat-colour for albino with
non-agouti, hooded phenotype (C, a, h) (Fig. 3b). Sequence
analysis at the targeted Tyr locus revealed indel mutations in
three pups (23.1%), and the precise SNP exchange in one pup
(7.7%) (Fig. 3c; Table 3).
Next, by injecting Cas9-gRNA:Asipa with ssODN:AsipA into
F344 embryos, we attempted targeted integration of a 19-bp
nucleotide fragment at the Asipa locus to recover the non-agouti
phenotype (Fig. 3a). Sequence analysis revealed that 5 of the 33
pups injected carried indel mutations (15.2%) at the targeted
Asipa locus while 6 pups carried the precisely repaired AsipA allele
KI (18.2%) (Fig. 3d; Table 3). To recover the hooded phenotype
by eliminating the large E7-kb fragment including an ERV and
two long terminal repeat sequences at either ends of the ERV, we
used two gRNAs:Kith-1 and:Kith-2 modules designed against the
outside sequences of the two long terminal repeats, and
ssODN:KitHconsisting of two times 60-bp each located at the
outer sides of the Cas9-cutting edges (Fig. 3a). Of the 25 pups that
were injected, 9 (36.0%) showed indel mutations at the Kith-1
locus, but no pups carried any mutations at the Kith-2 locus
(Fig. 3e; Table 3). However, DNA from one pup produced a
positive PCR band (405 bp) amplified by a primer set designed for
the outer sides adjacent to the two gRNA-targeting sequences
(Fig. 3f). Sequence analysis confirmed that the two cutting edges
were accurately joined, thereby comprising the final 120-bp
ssODN:KitH module (Fig. 3e). Finally, crossing the AsipA founder
(c, A, h) and the KitH founder (c, a, H) mediated by CRISPR/Cas
with black-hooded PVG/Seac rats (C, a, h) resulted in the
recovery of Agouti-hooded (C, A, h) and whole-body black
(C, a, H) rat coat-colour phenotypes, respectively (Supplementary
Figs 9 and 10).
Discussion
In this study, using the CRISPR/Cas platform in rats, we
successfully recovered three distinct coat-colour phenotypes:
albino (c) a missense mutation in the Tyr gene, non-agouti (a)
a 19-bp deletion in the Asip gene and hooded (h) an integration
of a 7,098-bp ERV elements in the Kit gene (Supplementary
Fig. 1). Yang et al.27 have recently reported CRISPR/Cas-
mediated genome editing in mice, including multiplexed
targeted KOs, and a precise SNP exchange using ssODN
donors26. They also created reporter and conditional KI alleles
with site-specific insertions of a short Tag or a long fluorescent
reporter, and double insertions of two loxP sites (floxed alleles),
respectively27. In rats, three papers have been reported for
CRISPR/Cas-mediated-targeted KOs12,28,29, and a more recent
paper38 generated targeted KIs of floxed alleles using double-
strand DNA (dsDNA) donor plasmids. However, accurate KIs
with ssODNs, such as that reported in mice26,27, have not yet
been demonstrated. To our knowledge, this is the first report to
demonstrate that the CRISPR/Cas system can be used for
accurate KI targeting with ssODNs in rats, thereby recovering
disease-associated phenotypes of various types of mutations, such
as SNPs, indels and large genomic structural variations.
Using the CRISPR/Cas system with ssODNs, we surprisingly
detected the high efficiency of HDR-mediated KIs in rats. In mice,
the high efficiency of HDR-mediated KIs has also been reported
with ssODN donors26,27,33, compared with those of KIs with
dsDNA donor vectors39. One of the major differences between
ssODNs and dsDNAs is the lengths of the inserted DNA, such as
1–35 bp versus several hundred base pairs, respectively. The larger
DNA fragment might be more difficult to integrate into target
sites via HDR. Differences in the underlying mechanisms for
HDR-based repair of CRISPR-mediated DSBs between ssODN
and dsDNA donors might also serve as an explanation for the
efficiency differences, although the exact repair mechanisms are
still unknown40,41. Although the CRISPR/Cas system with
ssODN donors in rats allowed us to mediate various kinds of
genome editing, such as SNP exchange, site-specific insertion of
short DNA fragment and a precise large DNA deletion, multiple
cleavages to investigate large-scale chromosomal rearrangements
is still a challenging task42,43.
Our CRISPR/Cas platform also facilitated allele-specific
genome editing. The allele-specific CRISPR/Cas targeted the
exact allele of the target gene by a specific gRNA that could
discriminate a single SNP of the targeted allele in heterozygous F1
rat hybrids. In the Cas9/gRNA-injected embryos, the specific
gRNA for the F344-albino mutation (gRNA:Tyrc) only targeted
the F344-allele (6/21), while the gRNA for DA-wild-type
(gRNA:TyrC) only targeted the DA-allele (7/23), thereby chan-
ging the dominant coat-colour phenotype of the F1 pups (Fig. 2c).
The allele-specific genome editing may be used for targeting genes
that affect disease-related phenotypes in a dominant-negative
Table 2 | CRISPR/Cas-mediated genome editing in F1 hybrids.
Microinjection Embryos injected* Two-cell embryos (%) Pups delivered (%) Tyrc-KO (%) TyrC-KO (%)
Cas9þ gRNA:Tyrc 104 48 (46.2) 21 (43.8) 6 (28.6) 0 (0)
Cas9þ gRNA:TyrC 135 71 (52.6) 23 (32.4) 0 (0) 7 (30.4)
*F1 embryos collected from the superovulated F344 female previously mated with DA males.
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manner. It may also be applicable to larger heterogeneous
populations in which it has proven difficult to create inbred lines,
or in human/primate cell lines or stem cells that are normally
genetically very heterogeneous. Our F1-hybrid experiments have
uncovered several additional findings that have not been observed
in homozygous inbred strains so far. The CRISPR/Cas-mediated














Cas9þ gRNA:Tyrcþ ssODN:TyrC 94 45 (47.9) 13 (28.9) 3 (23.1) 1 (7.7) – – – – –
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Figure 3 | Recovery of three distinct coat-colour mutations by CRISPR/Cas. (a) Schematic illustration of three coat-colour mutations in rats. albino (Tyrc):
SNP missense mutation in the Tyr gene. non-agouti (Asipa): 19-bp deletion in exon 2 of the Agouti signalling protein (Asip) gene. hooded (Kith): integration
of an 7,098-bp endogenous retrovirus (ERV) element within the first intron of the Kit gene. (b) Coat-colour phenotypes (C, a, h) recovered from albino by
injecting gRNA:Tyrc, Cas9 mRNA, and ssODN of the TyrC allele into F344 rat embryos (c, a, h). (c) Sequence analysis of the targeted Tyr exon 2 in the
injected F344 rats. Cas9 and gRNA with ssODN mediated the introduction of several indel mutations, and the precise HDR-mediated SNP exchange of TyrC.
(d) Recovery of the non-agouti phenotype by injecting gRNA:Asipa, Cas9 mRNA, and ssODN of the AsipA allele into F344 rat embryos. Cas9 and gRNA
with ssODN mediated the introduction of several indel mutations, and the precise short DNA fragment integration of the AsipA gene. (e) Recovery
of the hoodedmutation by injecting gRNA:Kith-1, gRNA:Kith-2, and ssODN of the KitH allele into F344 rat embryos. Cas9 and two gRNAs with ssODN mediated
the introduction of indel mutations at the targeted Kith-1 locus, and the precise large deletion between the two cutting edges of KitH. (f) PCR analysis
of the injected F344 rats using primers designed against each outer side of the two LTR sequences. M: DNA marker phiX174-HaeIII digest.
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F1 pups showed complete or mosaic albino phenotypes (Fig. 2c).
This indicates that the injected Cas9/gRNA carries out gene
editing at the one-cell stage for changing the complete phenotype
and at the two-cell stage (or later) for the mosaic phenotype, since
in F1 hybrids only one target-allele exists at the one-cell stage,
although there is the possibility that cleavage and/or repair
occurred later in the developmental stage. The fact that the
resulting CRISPR/Cas-mediated Wistar rat carried four muta-
tions (Supplementary Fig. 3), which were all faithfully transmitted
through the germline (Supplementary Table 1), also supports
these findings. Furthermore, although we injected gRNA:Tyrc (for
F344) into the DA-derived male pronucleus, the F344-allele of the
female pronucleus was modified in the embryos, suggesting that
the CRISPR/Cas-mediated gene editing presumably occurred
after the fusion of haploid gametes in the fertilized eggs.
Another novel finding allows conclusions regarding the
mechanistic level of the process that is initiated by the initial
DSB caused by the CRISPR/Cas system. The occurrence of albino
coat-colour rats that carry homozygous alleles of F344 Tyrcbut
were derived by injection of gRNA:TyrC into TyrC/ Tyrc F1-
hybrid embryos, suggests that interallelic gene conversion has
occurred (Supplementary Fig. 8). The gRNA:TyrC and Cas9
induced DSBs at the targeted DA TyrC allele. This DSB was
repaired using the F344 Tyrcallele as the template, resulting in an
interallelic gene conversion between homologous chromosomes.
Sequence analysis of the F1 rats with polymorphic SNPs between
F344 and DA revealed that the interallelic conversion occurred
beyond the 2-kb region of the targeted site, but did not exceed the
30-kb region around the site (Supplementary Fig. 11). These
findings provide an explanation as to how CRISPR/Cas can
mediate targeted homozygous mutations. The initially generated
KO allele in the haploid nucleus is used as the template for
repairing the subsequently mediated KO allele in the fused nuclei,
causing targeted homozygous alleles in the one-cell stage embryo.
These observations also suggest that CRISPR/Cas can be used for
allele-specific gene therapy by targeted gene silencing or targeted
gene conversion between homologous chromosomes to repair the
dominant disease-related allele.
The frequency of OT mutations remains one of the biggest
unknown variables concerning the use of CRISPR/Cas to modify
genomes20,34,44. In this study, genomic loci containing up to three
or four base-pair mismatches compared with the 20-bp gRNA
sequences were amplified by PCR. The most likely 7 OT sites of
gRNA:Tyr in 7 founder rats, 11 OTs of gRNA:Asip in 11 founder
rats, 4 OTs of gRNA:Kit-1 in 11 founder rats and 5 OTs of
gRNA:Kit-2 in another 11 founder rats were investigated
(Supplementary Tables 2 and 3). No indel mutations at any
of the examined potential OT sites were identified by sequence
analysis in the all CRISPR/Cas-mediated founder rats
(Supplementary Table 2). However, OT cleavages by CRISPR/
Cas have been reported in several individual studies using human
and rodent cells20,44. In general, the OT effects of CRISPR/Cas,
which depend on the 20-bp target sequences of the gRNA and the
terminal NGG protospacer adjacent motif sequences, seem to be
higher than those of ZFNs and TALENs, which depend on the
30- to 36-bp target sequences detected by the two engineered
proteins30. The double Cas9-nickase approach using the
enhanced cleavage specificity with 40-bp of double-target
sequences has been reported to reduce OT mutations20,45. Our
in vitro study using Rat-1 cells suggested higher cleavage
specificity of CRISPR/Cas than that of TALENs against the
albino mutation (Fig. 2b). General comparisons among the three
most recently used gene modifying systems (that is, ZFN, TALEN
and CRISPR/Cas) in terms of their efficiency and specificity are
not easy to make and can only be determined from case-by-case
studies. It is difficult to draw comparisons between TALEN and
CRISPR/Cas using our particular approach, since the targeted
mutation is located at the 30 critical sequences for gRNA
binding20,44, but is not important for TALE binding at the 50
sequence (Supplementary Fig. 12). The higher specificity of
CRISPR/Cas in this study might be explained by the specificity
of its DNA–RNA binding compared with that of the DNA–protein
binding in the ZFN/TALEN systems. In our experiments, sequence
analysis of Rat-1 cell DNA also revealed the presence of 5–8%
mismatched cleavages even with the allele-specific gRNA (Fig. 2d;
Supplementary Figs 4 and 5), while no mismatch cleavages
were detected in the F1 rat embryos (Fig. 2g; Supplementary
Figs 7 and 8). The difference in the cleavage specificity between the
in vitro cells and the in vivo embryos, even using the same target
sequences, might have been caused by differences in the protocols
that were used. The DNA plasmids that constitutively express
gRNA and Cas9 mRNA were transferred into Rat-1 cells, while the
gRNA and Cas9 mRNA that transiently translate the protein were
injected into rat embryos, resulting in shorter cleavage duration at
lower concentrations in embryos compared with that in cells.
Several in vivo studies reported in mice26,27, rats12,28,29 and other
animals21–23 suggests less OT cleavages compared with those in
in vitro studies20,34,44, thereby supporting our findings. In contrast
to cell-based experiments using any of the above described
nucleases, potential OT effects are normally crossed-out in animal
studies. Every backcross generation removes potential off-targeted
modifications by 50%, which means that only two times
backcrossing clears already 75% of the genome from
unintentional mutations that might have been induced by OT
effects. Provided a careful selection of the target region and
sophisticated design of the gRNA and considering a natural de
novo mutation rate of 70–175 newly acquired mutations per
diploid genome between two generations46,47, the number of
OT mutations induced by nucleases only plays a minor role in
this context.
In conclusion, we have shown that the CRISPR/Cas system
provides effective genome editing in rats, such as KOs, KIs, allele-
specific manipulations, gene conversion and the recovery of
disease-related mutations. This powerful and efficient genome-
editing technology can be used for creating animal models of
many important human diseases as well as for prospective gene
therapy approaches.
Methods
Animals. F344/Stm (NBRP-Rat No.0140), DA/Slc (NBRP-Rat No.0157) and PVG/
Seac (NBRP-Rat No.0080) rats were provided by the National Bio Resource Project
for the Rat in Japan (www.anim.med.kyoto-u.ac.jp/nbr). Jcl:Wistar rats were
obtained from CLEA Japan Inc. (Tokyo, Japan). The rats were kept under con-
ditions of 50% humidity and a 14:10-h light: dark cycle. They were fed a standard
pellet diet (F-2, Oriental Yeast Co. Ltd, Tokyo, Japan) and tap water ad libitum.
Animal care and experiments conformed to the Guidelines for Animal Experi-
ments of Kyoto University, and were approved by the Animal Research Committee
of the Kyoto University.
Cell culture and transfection by electroporation. Rat-1 cells were obtained from
the RIKEN BRC Cell Bank (Tsukuba, Japan, www.brc.riken.jp/lab/cell/english).
The cells were cultured in Dulbecco’s modified Eagle’s medium (Life Technologies,
Carlsbad, CA, USA), supplemented with 10% fetal bovine serum in a humidified
atmosphere containing 5% CO2 at 37 C. REFs were isolated from the E14.5
embryos of F344 and DA rats. The REFs were cultured in Dulbecco’s modified
Eagle’s medium supplemented with 10% fetal bovine serum. The Rat-1 cells and
REFs (1 105) were suspended in 10ml of R buffer (supplied as part of the Neon
Transfection System, Life Technologies) and each given 0.5 mg of the Cas9 and
gRNA plasmid, after which they were electroporated using the Neon Transfection
System (Life Technologies) under the following conditions: pulse voltage, 1,300V;
pulse width, 20ms; and pulse number, 2. The in vitro transfer experiment was
replicated three times.
Plasmids expressing codon-optimized Cas9 and gRNA. Plasmid vectors
expressing Cas9 and gRNA with the U6 promoter for transfection by electro-
poration (hCas9: ID#41815, and gRNA cloning vector: ID#41824, respectively),
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and with the T7 promoter for in vitro transcription (pMLM3613: ID#42251,
and pDR274: ID#42250, respectively), were obtained from the Addgene
repository (www.addgene.org/CRISPR). To design the gRNAs, software tools
(crispr.genome-engineering.org) predicting unique target sites throughout the rat
genome were used. Oligonucleotides designed for target sites were cloned into an
AflII-digested gRNA empty vector or into BsaI-digested pDR274. The target sites
in the rat genome and the sequences of the ssODNs are shown in Supplementary
Figs 12–14.
To prepare Cas9 mRNA and gRNA, T7-promoter Cas9 and gRNA expression
plasmids were linearized with XhoI and HindIII, respectively, and extracted with
NucleoSpin Gel and PCR Clean-up kits (Macherey-Nagel, Du¨ren, Germany). After
purification of the linearized DNA, Cas9 and gRNA mRNA were transcribed
in vitro using a MessageMAXT7 ARCA-Capped Message Transcription Kit
(CELLSCRIPT, Madison, WI, USA) and a MEGAshortscript T7 Kit (Life
Technologies), respectively. Cas9 mRNA was then polyadenylated using a A-Plus
Poly(A) polymerase tailing kit (CELLSCRIPT). The resultant mRNA was purified
using a MEGAClear kit (Life Technologies) and resuspended in RNase-free water.
Rat embryo microinjections. F344 and Wistar females of 8–12 weeks of age were
superovulated by injection with gonadotropin serum from pregnant mares (PMSG:
Aska Pharmaceutical Co., Tokyo, Japan) and human chorionic gonadotropin
(hCG: Aska Pharmaceutical Co.). Then, pronuclear-stage embryos were collected
from the superovulated females previously mated with males. They were cultured
in a modified Krebs-Ringer bicarbonate solution48 before and after the
microinjections49. Using a micromanipulator (Narishige, Tokyo, Japan),
100 ng ml 1 Cas9 mRNA and 50 ng ml 1 gRNA were microinjected into the male
pronuclei of the embryos. For the KI experiments, 50 ng ml 1 ssODN was co-
injected. Injected embryos were cultured in modified Krebs-Ringer bicarbonate
medium overnight and the divided two-cell embryos were transferred into
pseudopregnant Wistar females.
After microinjection, two-cell embryos were also collected. Genomic DNA was
amplified with the GenomePlex Single Cell Whole Genome Amplification Kit
(Sigma Aldrich, St Louis, MO, USA). After purification of the DNA, CRISPR/Cas-
mediated mutations at target sites were analysed by direct sequencing.
Cel-I nuclease assay and DNA sequence analysis. For the Cel-I nuclease assay
to detect CRISPR/Cas9-mediated mutations, the SURVEYOR Mutation Detection
Kit (Transgenomic, Omaha, NE, USA) was used in accordance with the manu-
facturer’s protocol. Briefly, 72 h after electroporation, genomic DNA was extracted
from the Rat-1 cells and REFs using Nucleospin Tissue XS (Macherey-Nagel). PCR
was then performed with the primers shown in Supplementary Figs 12–14. PCR
amplification products were denatured and digested by the Cel-I nuclease, and then
subjected to agarose gel electrophoresis.
For DNA sequence analysis, the PCR products were subcloned into a
pCR4Blunt-TOPO plasmid vector (Life Technologies). Plasmids were extracted
from the resultant Escherichia coli colonies for DNA sequencing. Sequencing was
performed using a BigDye Terminator Cycle Sequencing Kit and an ABI PRISM
3130 Genetic Analyzer (Life Technologies).
OT analysis. The potential OT sites in the rat genome (rn5) were identified using
the latest version of the CRISPR design tool (crispr.mit.edu). All the potential sites
were ranked by the OT hit score based on the predicted specificity34. To keep the
OT analysis reasonable in the context of this study, B10 potential sites were
investigated per modified locus. Since a fixed OT score across all loci would have
resulted in either too few or too many potentially examined OT sites, different
scores were determined as follows: high-ranked potential sites (gRNA:Tyrc and
gRNA:Asipa;40.8, gRNA:Kith-1;40.7, gRNA:Kith-2;40.3) were sequenced for OT
analysis in the founder rats (Supplementary Tables 2 and 3).
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